Medicare aims to level reimbursement playing field in fight between Elekta and Varian

Thu, 07/11/2013 - 12:45pm
Mass Device

A new reimbursement proposal from the Center for Medicare & Medicaid Services removes would level payments for brain tumor radiosurgery performed with technology from either Swedish Elekta and California-based Varian.

Varian logoElekta logo

A new proposal from the Centers for Medicare & Medicaid Services would help level at least 1 battlefield between radiosurgery devices makers Elekta (STO:EKTA B) and Varian Medical Systems (NYSE:VAR).

The reimbursement proposal would offer equal payment to healthcare providers conducting single-treatment radiosurgery for brain tumors, whether the procedure is conducted with Elekta's Gamma Knife or Varian's Linac.

The decision would reverse a 2012 measure, supported by Senate Majority Leader Harry Reid (D-Nev.), which would cut payments for Elekta's technology.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.